CCL7 and neoplasm: The authors initially identified CCL3 as a factor suppressing tumor growth in vivo; however, in contrast to CCL7, their screening approach under anti-PD-1 therapy suggests that it may also play a role in driving immune cell exclusion from the tumor site.